Search
BioXcel Therapeutics Inc
BTAIAdd to Watchlist
1.370USD
-0.040-2.84%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
42.30MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.84%
5 Days
+4.58%
1 Month
+15.13%
6 Months
-14.38%
Year to Date
-14.38%
1 Year
-30.46%
Key Figures
1.380Open
1.420High
333.37KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.23%Turnover Ratio
1.410Prev. Close
1.360Low
363.88KTurnover
LossP/E Static
-0.35P/B
0.00%Div Yield TTM
-207.56%ROA
8.08052wk High
0.60Volume Ratio
-59.60MNet Profit
27.07MShares
-4.7633EPS TTM
0.33Beta
-1766.94%ROE
1.01052wk Low
4.25%Amplitude
-37.38%Gross Margin
42.30MMarket Cap
2.47Reward/Risk
7.50%Risk Rate
TradingKey Stock Score of BioXcel Therapeutics Inc
Currency: USD Updated: 2026-07-01Key Insights
BioXcel Therapeutics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 116 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.80.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current strong trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioXcel Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
BioXcel Therapeutics Inc Highlights
StrengthsRisks
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Growing
The company is in a growing phase, with the latest annual income totaling USD 642.00K.
Fairly Valued
The company’s latest PE is -0.29, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.05M shares, increasing 19.34% quarter-over-quarter.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
12.800
Target Price
+807.80%
Upside Space
BioXcel Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BioXcel Therapeutics Inc Info
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Ticker SymbolBTAI
CompanyBioXcel Therapeutics Inc
CEOMehta (Vimal)
Websitehttps://www.bioxceltherapeutics.com/
Related Instruments
-0.64%
-0.05%
-0.23%
-1.64%
-2.41%
-2.95%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
FAQs
What is the current price of BioXcel Therapeutics Inc (BTAI)?
The current price of BioXcel Therapeutics Inc (BTAI) is 1.37.
What is the symbol of BioXcel Therapeutics Inc?
The ticker symbol of BioXcel Therapeutics Inc is BTAI.
What is the 52-week high of BioXcel Therapeutics Inc?
The 52-week high of BioXcel Therapeutics Inc is 8.08.
What is the 52-week low of BioXcel Therapeutics Inc?
The 52-week low of BioXcel Therapeutics Inc is 1.01.
What is the market capitalization of BioXcel Therapeutics Inc?
The market capitalization of BioXcel Therapeutics Inc is 37.09M.
Is BioXcel Therapeutics Inc (BTAI) currently rated as Buy, Hold, or Sell?
According to analysts, BioXcel Therapeutics Inc (BTAI) has an overall rating of Buy, with a price target of 12.80.
What is the Earnings Per Share (EPS TTM) of BioXcel Therapeutics Inc (BTAI)?
The Earnings Per Share (EPS TTM) of BioXcel Therapeutics Inc (BTAI) is -5.73.